Adrenoleukodystrophy

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
2 Unique sponsors
5 Unique IMPs
4 Commercial trials
Drug classes (ATC)
C Cardiology (ATC C) 1
J Anti-infectives (ATC J) 1
N Neurology/Psychiatry (ATC N) 1
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Azole antifungal 1 substance
Phase III: 2 Phase II: 1 Phase I (Other): 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

2 trials
  • Genetix Biotherapeutics Inc. Commercial
    ELIVALDOGENE AUTOTEMCEL
    2024-513904-33-00 4 countries 2020 n=11
    Ended
  • Minoryx Therapeutics S.L. Commercial
    LERIGLITAZONE
    2024-515104-39-00 3 countries 2024 n=15 Orphan
    Recruiting

Phase II

1 trial
  • Minoryx Therapeutics S.L. Commercial
    LERIGLITAZONE
    2024-513774-21-00 3 countries 2019 n=8 Orphan
    Ended

Phase I (Other)

1 trial
  • Minoryx Therapeutics S.L. Commercial
    CARBAMAZEPINE; GEMFIBROZIL; ITRACONAZOLE; LERIGLITAZONE
    2025-521508-23-00 1 country 2025 n=73 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Minoryx Therapeutics S.L. Commercial 3 Phase I (Other), Phase II, Phase III 1
Genetix Biotherapeutics Inc. Commercial 1 Phase III 0
New trials by year
2019
1
2020
1
2024
1
2025
1
← All indication landscapes